Postoperative Radiotherapy in the Treatment of Male Breast Carcinoma: a Single Institute Experience

Overview

Journal J Natl Med Assoc

Publisher Elsevier

Specialty General Medicine

Date 2006 Apr 21

PMID 16623069

Citations 6

Authors

Lale Atahan

Ferah Yildiz

Ugur Selek

Sait Sari

Murat Gurkaynak

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the outcomes of radiation therapy treatment of male patients with breast cancer in our single institutional cohort and discover possible adverse prognostic factors.

Methods: We retrospectively evaluated 42 male patients (median age 55; range 33-77 years) with breast cancer. Patients were irradiated postoperatively in 2 Gy/fraction/day to chest wall +/- lymphatics.

Results: Median follow-up was 29 months. Eleven patients had neoadjuvant and 36 patients had adjuvant Adriamycin-based chemotherapy. Nine patients (21%) had local or regional, two (5%) had distant, and one (2.5%) had both local and distant disease at the time of analysis. The actuarial five-year Overall Survival (OS) was 77%, whereas the actuarial five-year Disease-Free (DFS), Locoregional Recurrence-free (LRRFS), and Distant Metastases-Free (DMFS) survival rates were 45%, 69% and 66%, respectively. Univariate analysis of variables, including patient characteristics, treatment modalities and factors, and tumor characteristics, failed to show an association with LRRFS and DFS except percent positive nodal involvement > or = 30% and 50%.

Conclusion: Though radiotherapy seems quite effective in reducing local recurrence, we have revealed that male breast cancer patients in our cohort with extensive nodal involvement (PPNI >30% and 50%) appeared not to have had a significant benefit from postmastectomy irradiation and adjuvant CMF-based chemotherapy.

Citing Articles

Male breast cancer: a 30 year retrospective analysis from a tertiary cancer care centre.

Soni A, Verma Y, Chauhan A, Kaur P, Kaushal V, Paul D Ecancermedicalscience. 2023; 17:1551.

PMID: 37377689 PMC: 10292857. DOI: 10.3332/ecancer.2023.1551.

Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso).

Zongo N, Ouedraogo S, Korsaga-Some N, Some O, Go N, Ouangre E World J Surg Oncol. 2018; 16(1):4.

PMID: 29325566 PMC: 5765600. DOI: 10.1186/s12957-017-1297-y.

Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.

Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V BMC Cancer. 2016; 16:375.

PMID: 27377827 PMC: 4932666. DOI: 10.1186/s12885-016-2414-y.

Male breast carcinoma: radiotherapy contributed to favorable local control in two cases and related literature review.

Liu M, Wang Q, Liu B, Gao L, Wu D, Yang S Eur J Med Res. 2015; 20:94.

PMID: 26612408 PMC: 4662040. DOI: 10.1186/s40001-015-0173-x.

Male breast cancer: a clinicopathologic study of 42 patients in eastern India.

Shah S, Bhattacharyya S, Gupta A, Ghosh A, Basak S Indian J Surg Oncol. 2013; 3(3):245-9.

PMID: 23997516 PMC: 3444579. DOI: 10.1007/s13193-012-0163-1.

References

Giordano S, Cohen D, Buzdar A, Perkins G, Hortobagyi G . Breast carcinoma in men: a population-based study. Cancer. 2004; 101(1):51-7. DOI: 10.1002/cncr.20312. View

Bagley C, Wesley M, Young R, Lippman M . Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol. 1987; 10(1):55-60. DOI: 10.1097/00000421-198702000-00013. View

Sverdlov R, Barshack I, Bar Sade R, Baruch R, Dagan E, Feinmesser M . Genetic analyses of male breast cancer in Israel. Genet Test. 2001; 4(3):313-7. DOI: 10.1089/10906570050501579. View

Izquierdo M, Alonso C, de Andres L, Ojeda B . Male breast cancer. Report of a series of 50 cases. Acta Oncol. 1994; 33(7):767-71. DOI: 10.3109/02841869409083946. View

JOCHIMSEN P, Menck H, Winchester D . An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery. 1999; 126(4):775-80; discussion 780-1. View

Rosenblatt K, Thomas D, McTiernan A, Austin M, Stalsberg H, Stemhagen A . Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst. 1991; 83(12):849-54. DOI: 10.1093/jnci/83.12.849. View

Ottini L, Masala G, DAmico C, Mancini B, Saieva C, Aceto G . BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003; 63(2):342-7. View

DONEGAN W, Redlich P, Lang P, Gall M . Carcinoma of the breast in males: a multiinstitutional survey. Cancer. 1998; 83(3):498-509. DOI: 10.1002/(sici)1097-0142(19980801)83:3<498::aid-cncr19>3.0.co;2-r. View

Stierer M, Rosen H, Weitensfelder W, Hausmaninger H, Teleky B, Jakesz R . Male breast cancer: Austrian experience. World J Surg. 1995; 19(5):687-92; discussion 692-3. DOI: 10.1007/BF00295904. View

10.

Ciatto S, Iossa A, Bonardi R, Pacini P . Male breast carcinoma: review of a multicenter series of 150 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Tumori. 1990; 76(6):555-8. DOI: 10.1177/030089169007600608. View

11.

Struewing J, Brody L, Erdos M, Kase R, Giambarresi T, Smith S . Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet. 1995; 57(1):1-7. PMC: 1801253. View

12.

Ford D, Easton D, Stratton M, Narod S, Goldgar D, Devilee P . Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62(3):676-89. PMC: 1376944. DOI: 10.1086/301749. View

13.

Singletary S, Allred C, Ashley P, Bassett L, Berry D, Bland K . Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002; 20(17):3628-36. DOI: 10.1200/JCO.2002.02.026. View

14.

Dong C, Hemminki K . Second primary breast cancer in men. Breast Cancer Res Treat. 2001; 66(2):171-2. DOI: 10.1023/a:1010639429207. View

15.

. Proceedings of the American Society for Therapeutic Radiology and Oncology, 32nd annual meeting. October 15-19, 1990, Miami Beach, Florida. Abstracts. Int J Radiat Oncol Biol Phys. 1990; 19 Suppl 1:1-278. View

16.

Levine M, Bramwell V, Pritchard K, Norris B, Shepherd L, Findlay B . Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada.... J Clin Oncol. 1998; 16(8):2651-8. DOI: 10.1200/JCO.1998.16.8.2651. View

17.

Frank T, Deffenbaugh A, Reid J, Hulick M, Ward B, Lingenfelter B . Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002; 20(6):1480-90. DOI: 10.1200/JCO.2002.20.6.1480. View

18.

GUINEE V, Olsson H, Moller T, Shallenberger R, Van den Blink J, Peter Z . The prognosis of breast cancer in males. A report of 335 cases. Cancer. 1993; 71(1):154-61. DOI: 10.1002/1097-0142(19930101)71:1<154::aid-cncr2820710125>3.0.co;2-#. View

19.

Auvinen A, Curtis R, Ron E . Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst. 2002; 94(17):1330-2. DOI: 10.1093/jnci/94.17.1330. View

20.

Ragaz J, Jackson S, Le N, Plenderleith I, Spinelli J, Basco V . Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997; 337(14):956-62. DOI: 10.1056/NEJM199710023371402. View